<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Ca(2+) is a highly versatile intracellular second messenger in the central <z:mp ids='MP_0008912'>nervous</z:mp> system, and regulates many complicated cellular processes, including excitation, plasticity and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="1" pm="."><plain>Influx of Ca(2+) from the extracellular fluid is required for sustained elevation of the cytosolic Ca(2+) concentration and full activation of Ca(2+)-dependent processes </plain></SENT>
<SENT sid="2" pm="."><plain>Voltage-dependent Ca(2+) channels (VDCCs) serve as the principal routes of Ca(2+) entry into electrically excitable cells such as neurons </plain></SENT>
<SENT sid="3" pm="."><plain>The <z:mp ids='MP_0008912'>nervous</z:mp> system expresses VDCCs with unique cellular and subcellular distribution and specific functions </plain></SENT>
<SENT sid="4" pm="."><plain>L-type voltage-dependent Ca(2+) channels (L-VDCCs) are distributed at neuronal cell bodies, dendrites and spines, and the postsynaptic L-VDCCs regulate neuronal excitability and gene expression </plain></SENT>
<SENT sid="5" pm="."><plain>Presynaptic P/Qand N-type VDCCs trigger neurotransmitter release, and T-type channels support neuronal rhythmic burst firing </plain></SENT>
<SENT sid="6" pm="."><plain>Evidence from natural mutants, knockout mice, and human <z:e sem="disease" ids="C0019247" disease_type="Disease or Syndrome" abbrv="">genetic disorders</z:e> indicates a fundamental role of some VDCCs in a wide variety of <z:e sem="disease" ids="C1112108" disease_type="Disease or Syndrome" abbrv="">neurological disorders</z:e>, including vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> (VaD), <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> (AD), <z:e sem="disease" ids="C0030567" disease_type="Disease or Syndrome" abbrv="PD">Parkinson's disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>) and <z:e sem="disease" ids="C0162534" disease_type="Disease or Syndrome" abbrv="">Prion disease</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Amyloid β <z:chebi fb="7" ids="16670">peptides</z:chebi>, causative factors for AD, potentiate the influx of Ca(2+) into neurons via L-VDCCs </plain></SENT>
<SENT sid="8" pm="."><plain>L-VDCCs blockers prevent neurons from undergoing amyloid β-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="9" pm="."><plain>The present review highlights some recent findings on biochemical characterizations, physiological functions, pathological roles and pharmacological applications of the L-VDCCs and their implication in <z:e sem="disease" ids="C1456669" disease_type="Disease or Syndrome" abbrv="">neurologic diseases</z:e> </plain></SENT>
</text></document>